RxDoctor Payments Data

Hong Hung Ho, MD

Ophthalmology · Artesia, CANPI 1245483445

Payments from drug & device makers

$2,381in general payments, 2019–2025

Across 28 payments — averaging $85.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • NEW World Medical,inc.$87
  • Alcon$67
  • Rxsight Inc$62
  • Alimera Sciences, Inc.$60
  • Bausch & Lomb Americas Inc.$41
  • plus $165 from 7 others

What the payments were for

  • Travel & lodging$1,71372%
  • Food & beverage$66728%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,381 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$465,197
Medicare patients
509
Services billed
5,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$28,211
LumiganBimatoprost33$18,582
RhopressaNetarsudil Mesylate31$18,229
Cyclosporine19$11,479
RocklatanNetarsudil Mesylat/Latanoprost25$11,062
ProlensaBromfenac Sodium30$10,786
VyzultaLatanoprostene Bunod15$10,115
Latanoprost620$9,671
Prednisolone Acetate284$7,692
Bromfenac Sodium35$7,103
Difluprednate98$6,910
SimbrinzaBrinzolamide/Brimonidine Tart16$6,810
Brimonidine Tartrate202$5,631
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$4,815
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat192$4,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$22$46,79351 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$24$29,29156 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$41$10,78630 claims
Bausch & Lomb Americas Inc.Vyzulta$41$10,11515 claims
AlconSimbrinza$67$6,81016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Artesia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →